TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from SSY Group ( (HK:2005) ) is now available.
SSY Group Limited has announced that its products, Bilastine and Sodium Picosulfate, have received approval from the National Medical Products Administration of China for market preparation as bulk drugs. This development is significant for the company as it enhances its product offerings in the pharmaceutical market, potentially strengthening its position and providing new opportunities for growth.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates within the pharmaceutical industry, focusing on the development and production of medical products. The company is known for its range of pharmaceutical products, including bulk drugs, which cater to various medical needs.
Average Trading Volume: 12,904,034
Technical Sentiment Signal: Hold
Current Market Cap: HK$9.21B
Learn more about 2005 stock on TipRanks’ Stock Analysis page.